RxDoctor Payments Data

Karen Stewart

Family · North Chesterfield, VANPI 1780092395

Payments from drug & device makers

$2,079in general payments, 2019–2025

Across 77 payments — averaging $27.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$493
  • Cvrx, Inc.$326
  • Scpharmaceuticals Inc.$303
  • Merck$244
  • Kestra Medical Technology Services, Inc.$174
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$139
  • plus $402 from 7 others

What the payments were for

  • Food & beverage$2,079100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,079 in reported general payments places this provider in the 80th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$12,561
Medicare patients
44
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan118$139,018
JardianceEmpagliflozin44$44,732
FarxigaDapagliflozin Propanediol42$43,772
Metoprolol Succinate48$1,216
Carvedilol64$1,056
Bumetanide29$889
Torsemide39$812
Spironolactone63$544
Isosorbide Mononitrate ErIsosorbide Mononitrate22$529
Furosemide104$452
Potassium Chloride25$410
Hydralazine Hcl11$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$72$139,018118 claims
Boehringer IngelheimJardiance$493$44,73244 claims
AstraZenecaFarxiga$107$43,77242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,332 family providers in Virginia.

Other family in North Chesterfield

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →